New immune therapy targets Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new drug called RPTR-1-201, which helps the immune system attack cancer cells. It is for adults with advanced solid tumors that cannot be cured with standard treatments. The study will check safety and whether the drug shrinks tumors, both alone and…
Phase: PHASE1, PHASE2 • Sponsor: Repertoire Immune Medicines • Aim: Disease control
Last updated May 11, 2026 20:52 UTC